Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IONS

Ionis Pharmaceuticals Inc

Dec 07 • 02:28PM ET

49.56

Dollar change -0.38
Percentage change -0.76	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.86	Insider Own	2.25%	Shs Outstand	142.06M	Perf Week	0.18%
Market Cap	7.11B	Forward P/E	-	EPS next Y	-3.58	Insider Trans	-1.38%	Shs Float	140.24M	Perf Month	3.88%
Income	-409.02M	PEG	-	EPS next Q	-0.90	Inst Own	97.34%	Short Float / Ratio	6.95% / 8.69	Perf Quarter	20.26%
Sales	615.14M	P/S	11.56	EPS this Y	-74.58%	Inst Trans	-4.79%	Short Interest	9.74M	Perf Half Y	18.99%
Book/sh	2.20	P/B	22.53	EPS next Y	-7.86%	ROA	-15.27%	Target Price	54.00	Perf Year	30.32%
Cash/sh	15.58	P/C	3.18	EPS next 5Y	-	ROE	-89.91%	52W Range	32.69 - 51.89	Perf YTD	31.22%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-17.94%	52W High	-4.49%	Beta	0.47
Dividend %	-	Quick Ratio	6.33	Sales past 5Y	10.48%	Gross Margin	94.48%	52W Low	51.61%	ATR	1.48
Employees	796	Current Ratio	6.39	Sales Q/Q	-9.74%	Oper. Margin	-90.32%	RSI (14)	54.30	Volatility	3.19% 3.10%
Optionable	Yes	Debt/Eq	6.26	EPS Q/Q	-210.76%	Profit Margin	-66.49%	Rel Volume	0.41	Prev Close	49.94
Shortable	Yes	LT Debt/Eq	6.23	Earnings	Nov 02 BMO	Payout	-	Avg Volume	1.12M	Price	49.56
Recom	2.17	SMA20	0.91%	SMA50	5.05%	SMA200	21.06%	Volume	356,314	Change	-0.76%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-23-23	Upgrade	BofA Securities	Underperform → Neutral	$33 → $52
Sep-29-23	Initiated	Raymond James	Strong Buy	$63
Jul-31-23	Upgrade	Citigroup	Neutral → Buy	$36 → $60
Jun-07-23	Resumed	Piper Sandler	Overweight	$58
May-04-23	Upgrade	Citigroup	Sell → Neutral	$30 → $36
Mar-21-23	Initiated	Bernstein	Underperform	$31
Dec-21-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $40
Sep-09-22	Resumed	Morgan Stanley	Overweight	$57
Jul-18-22	Resumed	Oppenheimer	Outperform	$59
Mar-31-22	Resumed	Piper Sandler	Overweight	$54
Mar-01-22	Initiated	Guggenheim	Buy	$64
Mar-01-22	Initiated	Citigroup	Sell	$26
Feb-01-22	Downgrade	BofA Securities	Buy → Underperform	$40 → $30
Dec-14-21	Upgrade	William Blair	Mkt Perform → Outperform
May-07-21	Upgrade	UBS	Sell → Neutral	$33 → $37.50
Mar-01-21	Upgrade	Barclays	Underweight → Equal Weight	$50 → $52
Dec-16-20	Initiated	UBS	Sell	$34
Dec-15-20	Upgrade	Cowen	Market Perform → Outperform
Sep-14-20	Resumed	JP Morgan	Neutral	$63
Sep-02-20	Initiated	The Benchmark Company	Hold

Show Previous Ratings

Nov-16-23 08:00AM	Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies (GlobeNewswire)
Nov-13-23 09:46AM	Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise (Zacks)
Nov-11-23 11:30AM	Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome (PR Newswire)
Nov-09-23 12:42PM	Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema (PR Newswire)
Nov-04-23 01:01PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Call Transcript (Insider Monkey)
06:36PM	Loading…
Nov-03-23 06:36PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +7.91%
09:44AM	Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
05:09AM	Q3 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-02-23 12:36PM	Ionis Pharmaceuticals Inc (IONS) Reports Q3 2023 Financial Results (GuruFocus.com)
09:30AM	Ionis Pharmaceuticals (IONS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:19AM	Ionis Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Ionis reports third quarter 2023 financial results (PR Newswire)
Oct-31-23 10:01AM	Amneal Pharmaceuticals (AMRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:02AM	Loading…
Oct-26-23 10:02AM	Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-19-23 07:05AM	Ionis to hold third quarter 2023 financial results webcast (PR Newswire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-05-23 10:26AM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +7.28%
Oct-04-23 07:00AM	Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization (PR Newswire)
Oct-02-23 01:17PM	Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day (GlobeNewswire)
Sep-30-23 05:10AM	Insider Sell: EVP, Chief Scientific Officer C Bennett Sells 4,460 Shares of Ionis ... (GuruFocus.com)
Sep-29-23 05:01AM	Insider Sell: Director B Parshall Sells 10,000 Shares of Ionis Pharmaceuticals Inc (GuruFocus.com)
Sep-28-23 12:02PM	Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit (PR Newswire)
10:06AM	Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs (Zacks)
Sep-27-23 09:58AM	Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5% (Zacks)
08:00AM	Strength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength? (Zacks)
07:00AM	Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease (PR Newswire)
Sep-26-23 04:19PM	Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder (Investor's Business Daily) +8.49%
07:28AM	UPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in study (Reuters)
07:10AM	Loading…
07:10AM	Ionis Pharma's genetic disorder drug meets main goal in late-stage study (Reuters)
07:00AM	Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome (PR Newswire)
Sep-20-23 01:03PM	The 7 Most Hated Stocks by Institutional Traders (InvestorPlace)
Sep-12-23 07:05AM	Ionis to host investor and analyst day event (PR Newswire) +5.38%
Sep-08-23 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report? (Zacks)
Aug-30-23 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Aug-11-23 12:37PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 11:31AM	Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates (Zacks)
10:04AM	Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised) (Zacks)
09:55AM	Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised) (Zacks)
04:56AM	Q2 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
01:01AM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Aug-09-23 09:30AM	Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:09AM	Ionis Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Ionis reports second quarter 2023 financial results (PR Newswire)
Aug-03-23 07:05AM	Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease (PR Newswire)
Jul-31-23 07:05AM	Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy (PR Newswire)
Jul-28-23 07:05AM	Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America (PR Newswire)
Jul-26-23 07:05AM	Ionis to hold second quarter 2023 financial results webcast (PR Newswire)
Jul-17-23 06:59AM	BridgeBio unveils positive results from rare heart disease drug trial, shares jump (Investing.com)
Jul-11-23 09:40AM	Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study (Zacks)
Jul-10-23 07:05AM	Eplontersen continued to show improvement in ATTRv-PN through 85 weeks (PR Newswire)
Jul-05-23 07:05AM	Ionis to present at upcoming investor conference (PR Newswire)
Jun-30-23 04:08PM	New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy (PR Newswire)
04:06PM	New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy (GlobeNewswire)
Jun-09-23 11:30AM	Catalyst (CPRX) Down 16.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-08-23 01:09AM	Ionis prices private placement of convertible senior notes (PR Newswire)
Jun-07-23 10:30AM	I've Got My Eye On Ionis Pharmaceuticals for Higher Highs (TheStreet.com) -6.42%
Jun-06-23 04:01PM	Ionis announces proposed private placement of convertible notes (PR Newswire)
Jun-02-23 11:31AM	Ionis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-01-23 07:05AM	Ionis announces positive donidalorsen late-stage clinical progress in HAE (PR Newswire)
May-24-23 02:23PM	Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 (Investor's Business Daily)
May-19-23 07:11PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research) +6.99%
May-10-23 07:05AM	Ionis to host 2023 virtual Annual Meeting of Stockholders (PR Newswire)
May-09-23 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
May-04-23 08:58AM	Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match (Zacks)
04:10AM	Q1 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 08:20PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
09:30AM	Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q1 Earnings (Zacks)
08:15AM	Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:06AM	Ionis Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
07:00AM	Ionis reports first quarter 2023 financial results (PR Newswire)
Apr-27-23 10:03AM	Avalo Therapeutics, Inc. (AVTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-26-23 10:01AM	Earnings Preview: Ionis Pharmaceuticals (IONS) Q1 Earnings Expected to Decline (Zacks)
Apr-25-23 07:10PM	FDA approves QALSODY (tofersen) as the first treatment targeting a genetic cause of ALS (PR Newswire)
Apr-24-23 02:37PM	3 Biotech Stocks to Sell Before Theyre 6 Feet Under (InvestorPlace)
07:00AM	Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks (PR Newswire)
Apr-20-23 07:05AM	Ionis to hold first quarter 2023 financial results webcast (PR Newswire)
Apr-19-23 09:15AM	Could This Rare-Disease Drug Candidate Become a Blockbuster? (Motley Fool)
Mar-29-23 08:45AM	New data presented at AD/PD2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease (PR Newswire)
Mar-28-23 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Mar-27-23 01:21PM	AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review (Benzinga)
11:42AM	Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study (Zacks)
02:00AM	Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN (PR Newswire)
Mar-24-23 11:30AM	Why Is Ionis Pharmaceuticals (IONS) Down 8.4% Since Last Earnings Report? (Zacks)
Mar-23-23 04:03PM	Biogen Pops But Ionis Hands Back Gains After ALS Drug Wins A Key Endorsement (Investor's Business Daily)
09:25AM	Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement (Investor's Business Daily)
Mar-22-23 11:01PM	Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS (PR Newswire)
Mar-09-23 07:31PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
Mar-07-23 07:05AM	Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) (PR Newswire)
Feb-28-23 07:05AM	Ionis to present at upcoming investor conferences (PR Newswire)
Feb-23-23 04:33PM	Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2022 Earnings Call Transcript (Insider Monkey)
09:15AM	Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down (Zacks)
Feb-22-23 05:49PM	Analyst Report: Ionis Pharmaceuticals, Inc. (Morningstar Research)
08:15AM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:01AM	Ionis reports fourth quarter and full year 2022 financial results (PR Newswire)
Feb-21-23 02:51PM	Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile' (Benzinga)
07:05AM	Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting (PR Newswire)
Feb-16-23 10:01AM	Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline (Zacks)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KLEIN JOSEPH III	Director	Nov 15	Sale	50.00	2,000	100,000	16,346	Nov 17 04:58 PM
Swayze Eric	EVP Research	Oct 17	Sale	47.95	52	2,493	73	Oct 18 06:40 PM
Swayze Eric	EVP Research	Oct 16	Option Exercise	0.00	125	0	125	Oct 18 06:40 PM
Monia Brett P	Chief Executive Officer	Oct 12	Sale	46.00	3,770	173,420	118,111	Oct 16 04:35 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Sep 28	Sale	46.50	4,460	207,390	65,754	Sep 29 05:20 PM
PARSHALL B LYNNE	Director	Sep 26	Sale	45.13	10,000	451,268	82,588	Sep 28 06:03 PM
KLEIN JOSEPH III	Director	Sep 26	Sale	45.13	2,000	90,254	18,346	Sep 28 06:03 PM
Diaz Allene M.	Director	Aug 01	Sale	41.05	657	26,970	12,676	Aug 03 05:20 PM
KLEIN JOSEPH III	Director	Jul 18	Sale	42.00	3,555	149,310	20,346	Jul 19 06:05 PM
WENDER JOSEPH H	Director	Jul 17	Option Exercise	0.00	7,110	0	112,079	Jul 19 06:08 PM
Diaz Allene M.	Director	Jul 17	Option Exercise	0.00	5,333	0	13,333	Jul 19 06:05 PM
Hayden Michael R	Director	Jul 17	Option Exercise	0.00	7,110	0	30,219	Jul 19 06:05 PM
HERMAN JOAN E	Director	Jul 17	Option Exercise	0.00	7,110	0	37,330	Jul 19 06:05 PM
KLEIN JOSEPH III	Director	Jul 17	Option Exercise	0.00	7,110	0	23,901	Jul 19 06:05 PM
LOSCALZO JOSEPH	Director	Jul 17	Option Exercise	0.00	7,110	0	41,082	Jul 19 06:06 PM
PARSHALL B LYNNE	Director	Jul 17	Option Exercise	0.00	7,110	0	92,588	Jul 19 06:06 PM
BERTHELSEN SPENCER R	Director	Jul 17	Option Exercise	0.00	7,110	0	147,257	Jul 19 06:05 PM
Monia Brett P	Chief Executive Officer	Jul 07	Sale	42.25	18,650	787,953	121,724	Jul 11 05:07 PM
BERTHELSEN SPENCER R	Director	Jun 20	Option Exercise	28.47	11,250	320,288	140,147	Jun 22 05:17 PM
HERMAN JOAN E	Director	Jun 12	Option Exercise	0.00	3,555	0	30,220	Jun 14 04:50 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	May 24	Sale	41.70	1,527	63,676	40,355	May 24 08:25 PM
Monia Brett P	Chief Executive Officer	May 22	Sale	40.14	4,931	197,907	140,374	May 24 08:25 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 18	Sale	36.50	3,880	141,631	10,571	Apr 19 08:18 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Apr 18	Sale	36.50	2,582	94,250	24,312	Apr 19 08:18 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 18	Sale	36.50	672	24,530	36,528	Apr 19 08:18 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Apr 17	Option Exercise	0.00	5,667	0	26,894	Apr 19 08:18 PM
Birchler Brian	EVP, Corp and Development Ops	Apr 17	Option Exercise	0.00	1,875	0	37,200	Apr 19 08:18 PM
Baroldi Joseph	EVP, Chief Business Officer	Apr 17	Option Exercise	0.00	10,838	0	14,451	Apr 19 08:18 PM
Monia Brett P	Chief Executive Officer	Feb 06	Sale	40.69	24,651	1,003,153	145,305	Feb 07 05:36 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Feb 06	Sale	40.59	2,079	84,392	75,496	Feb 07 05:36 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Feb 06	Sale	40.86	1,920	78,460	41,581	Feb 07 05:37 PM
Geary Richard S	EVP, Chief Development Officer	Feb 06	Sale	40.66	1,920	78,070	72,385	Feb 07 05:36 PM
Swayze Eric	EVP Research	Feb 06	Sale	40.79	1,815	74,031	31,941	Feb 07 05:37 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Feb 06	Sale	40.57	1,813	73,560	69,651	Feb 07 05:36 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Feb 06	Sale	40.66	1,451	58,997	21,227	Feb 07 05:36 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Feb 06	Sale	40.67	1,413	57,464	24,946	Feb 07 05:37 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 31	Sale	39.71	4,500	178,700	39,679	Feb 02 01:48 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 30	Sale	39.42	4,500	177,372	44,179	Feb 02 01:48 PM
Monia Brett P	Chief Executive Officer	Jan 18	Sale	39.49	25,066	989,947	120,863	Jan 19 08:21 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 18	Sale	39.70	8,280	328,721	73,435	Jan 19 08:19 PM
Geary Richard S	EVP, Chief Development Officer	Jan 18	Sale	39.57	7,873	311,525	70,483	Jan 19 08:19 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 18	Sale	39.49	7,836	309,480	48,679	Jan 19 08:21 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 18	Sale	38.89	6,978	271,356	67,855	Jan 19 08:19 PM
Swayze Eric	EVP Research	Jan 18	Sale	39.74	5,631	223,800	30,041	Jan 19 08:22 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 18	Sale	39.57	4,752	188,052	22,326	Jan 19 08:22 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 18	Sale	39.55	3,748	148,223	18,538	Jan 19 08:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 18	Sale	39.79	375	14,920	851	Jan 19 08:19 PM
Baroldi Joseph	EVP, Chief Business Officer	Jan 17	Option Exercise	0.00	904	0	1,226	Jan 19 08:19 PM
BENNETT C FRANK	EVP, Chief Scientific Officer	Jan 17	Option Exercise	0.00	19,417	0	74,833	Jan 19 08:19 PM
Cadoret-Manier Onaiza	EVP, Chf GL Pdt Str & Oper Ofc	Jan 17	Option Exercise	0.00	10,197	0	22,286	Jan 19 08:19 PM
Geary Richard S	EVP, Chief Development Officer	Jan 17	Option Exercise	0.00	21,983	0	78,356	Jan 19 08:19 PM
HOUGEN ELIZABETH L	EVP, Finance & CFO	Jan 17	Option Exercise	0.00	23,154	0	81,715	Jan 19 08:19 PM
Schneider Eugene	EVP, Chf Clinical Develop Ofcr	Jan 17	Option Exercise	0.00	13,046	0	27,078	Jan 19 08:22 PM
Monia Brett P	Chief Executive Officer	Jan 17	Option Exercise	0.00	57,267	0	145,929	Jan 19 08:21 PM
O'NEIL PATRICK R.	EVP CLO & General Counsel	Jan 17	Option Exercise	0.00	21,871	0	56,515	Jan 19 08:21 PM
Swayze Eric	EVP Research	Jan 17	Option Exercise	0.00	15,780	0	35,672	Jan 19 08:22 PM
KLEIN JOSEPH III	Director	Jan 17	Sale	40.00	2,000	80,000	16,791	Jan 18 08:19 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IONS

Ionis Pharmaceuticals Inc

Upgrade your FINVIZ experience